New hope for tough breast cancers: adding Low-Dose chemo to standard treatment
NCT ID NCT07467330
Summary
This study aims to see if adding a low-dose, continuous chemotherapy pill (capecitabine) to a standard two-drug treatment works better for controlling advanced breast cancer that has spread to internal organs like the liver or lungs. It will involve 258 women whose cancer is hormone-sensitive but has returned or spread. Participants will be randomly assigned to receive either the standard two-drug combo or the standard combo plus the low-dose chemo pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hosptial
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.